TY - JOUR
T1 - Carotenoids in Age-related maculopathy Italian study (CARMIS)
T2 - Two-year results of a randomized study
AU - Piermarocchi, Stefano
AU - Saviano, Sandro
AU - Parisi, Vincenzo
AU - Tedeschi, Massimiliano
AU - Panozzo, Giacomo
AU - Scarpa, Giuseppe
AU - Boschi, Giorgio
AU - Giudice, Giuseppe Lo
PY - 2012/4
Y1 - 2012/4
N2 - Purpose. The high concentration of carotenoids in the macula, plus evidence linking oxidative stress to age-related macular degeneration (AMD) and carotenoids to antioxidation, generated the hypothesis that higher antioxidant intakes can prevent AMD. The aim of this study was to determine whether nutritional supplementation with a targeted nutritional supplement improves visual acuity and visual function in AMD. Methods. In this multicenter, prospective open-label randomized study, 145 patients were randomly assigned to 2 different treatment groups. Interventions were lutein (10 mg), zeaxanthin (1 mg), astaxanthin (4 mg; AZYR SIFI, Catania, Italy), and antioxidants/vitamins supplementation formula or no dietary supplementation for 2 years. Primary outcome was mean changes in visual acuity (VA) at 12 and 24 months. Other measures included contrast sensitivity (CS) and National Eye Institute visual function questionnaire (NEI VFQ-25) scores at 12 and 24 months. Results. Patients in the treated group showed stabilization of VA with significantly (p=0.003) better VA scores (81.4±7.2) compared to the nontreated group (76.8±8.9) at 24-month follow-up. An improvement in CS (p=0.001) and final mean NEI VFQ-25 composite scores at 12 and 24 months higher in treated group compared to nontreated group were also shown (p
AB - Purpose. The high concentration of carotenoids in the macula, plus evidence linking oxidative stress to age-related macular degeneration (AMD) and carotenoids to antioxidation, generated the hypothesis that higher antioxidant intakes can prevent AMD. The aim of this study was to determine whether nutritional supplementation with a targeted nutritional supplement improves visual acuity and visual function in AMD. Methods. In this multicenter, prospective open-label randomized study, 145 patients were randomly assigned to 2 different treatment groups. Interventions were lutein (10 mg), zeaxanthin (1 mg), astaxanthin (4 mg; AZYR SIFI, Catania, Italy), and antioxidants/vitamins supplementation formula or no dietary supplementation for 2 years. Primary outcome was mean changes in visual acuity (VA) at 12 and 24 months. Other measures included contrast sensitivity (CS) and National Eye Institute visual function questionnaire (NEI VFQ-25) scores at 12 and 24 months. Results. Patients in the treated group showed stabilization of VA with significantly (p=0.003) better VA scores (81.4±7.2) compared to the nontreated group (76.8±8.9) at 24-month follow-up. An improvement in CS (p=0.001) and final mean NEI VFQ-25 composite scores at 12 and 24 months higher in treated group compared to nontreated group were also shown (p
KW - Age-related macular degeneration
KW - Carotenoids
KW - Lutein
KW - Macular pigment
KW - Zeaxanthin
UR - http://www.scopus.com/inward/record.url?scp=84857609672&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84857609672&partnerID=8YFLogxK
U2 - 10.5301/ejo.5000069
DO - 10.5301/ejo.5000069
M3 - Article
C2 - 22009916
AN - SCOPUS:84857609672
VL - 22
SP - 216
EP - 225
JO - European Journal of Ophthalmology
JF - European Journal of Ophthalmology
SN - 1120-6721
IS - 2
ER -